Novavax, Inc. (NVAX): Price and Financial Metrics
NVAX Price/Volume Stats
Current price | $4.78 | 52-week high | $11.36 |
Prev. close | $4.85 | 52-week low | $3.53 |
Day low | $4.76 | Volume | 3,615,175 |
Day high | $4.95 | Avg. volume | 8,629,920 |
50-day MA | $4.61 | Dividend yield | N/A |
200-day MA | $6.34 | Market Cap | 668.98M |
NVAX Stock Price Chart Interactive Chart >
NVAX POWR Grades
- NVAX scores best on the Value dimension, with a Value rank ahead of 77.51% of US stocks.
- The strongest trend for NVAX is in Quality, which has been heading down over the past 26 weeks.
- NVAX ranks lowest in Stability; there it ranks in the 1st percentile.
NVAX Stock Summary
- NOVAVAX INC's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than just 4.87% of US listed stocks.
- Equity multiplier, or assets relative to shareholders' equity, comes in at -2.41 for NOVAVAX INC; that's greater than it is for only 4.92% of US stocks.
- With a year-over-year growth in debt of -49.3%, NOVAVAX INC's debt growth rate surpasses merely 5.16% of about US stocks.
- If you're looking for stocks that are quantitatively similar to NOVAVAX INC, a group of peers worth examining would be GSIT, MRKR, FULC, BCDA, and CRIS.
- NVAX's SEC filings can be seen here. And to visit NOVAVAX INC's official web site, go to www.novavax.com.
NVAX Valuation Summary
- In comparison to the median Healthcare stock, NVAX's price/earnings ratio is 103.43% lower, now standing at -1.
- NVAX's EV/EBIT ratio has moved up 11.9 over the prior 243 months.
Below are key valuation metrics over time for NVAX.
Stock | Date | P/S | P/B | P/E | EV/EBIT |
---|---|---|---|---|---|
NVAX | 2023-12-29 | 0.5 | -0.8 | -1.0 | -0.2 |
NVAX | 2023-12-28 | 0.6 | -0.9 | -1.1 | -0.3 |
NVAX | 2023-12-27 | 0.6 | -0.9 | -1.1 | -0.3 |
NVAX | 2023-12-26 | 0.6 | -0.9 | -1.1 | -0.3 |
NVAX | 2023-12-22 | 0.6 | -0.9 | -1.1 | -0.3 |
NVAX | 2023-12-21 | 0.6 | -0.9 | -1.1 | -0.3 |
NVAX Growth Metrics
- The 3 year cash and equivalents growth rate now stands at 1390.08%.
- The 5 year revenue growth rate now stands at 7.39%.
- Its 4 year net income to common stockholders growth rate is now at 53.22%.
The table below shows NVAX's growth in key financial areas (numbers in millions of US dollars).
Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
---|---|---|---|
2022-12-31 | 1,981.872 | -415.937 | -657.939 |
2022-09-30 | 1,846.673 | -640.529 | -1,321.974 |
2022-06-30 | 1,290.94 | -743.964 | -1,475.792 |
2022-03-31 | 1,403.032 | -428.649 | -1,317.624 |
2021-12-31 | 1,146.29 | 322.946 | -1,743.751 |
2021-09-30 | 1,203.749 | 536.786 | -1,075.031 |
NVAX's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- NVAX has a Quality Grade of C, ranking ahead of 58.82% of graded US stocks.
- NVAX's asset turnover comes in at 0.6 -- ranking 60th of 680 Pharmaceutical Products stocks.
- GTHX, SRRA, and OPK are the stocks whose asset turnover ratios are most correlated with NVAX.
The table below shows NVAX's key quality metrics over time.
Period | Asset Turnover | Gross Margin | ROIC |
---|---|---|---|
2021-06-30 | 0.600 | 1 | -14.595 |
2021-03-31 | 0.606 | 1 | -1.737 |
2020-12-31 | 0.502 | 1 | -0.781 |
2020-09-30 | 0.345 | 1 | -0.602 |
2020-06-30 | 0.126 | 1 | -0.222 |
2020-03-31 | 0.084 | 1 | -0.295 |
NVAX Price Target
For more insight on analysts targets of NVAX, see our NVAX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
Average Price Target | $264.20 | Average Broker Recommendation | 1.58 (Moderate Buy) |
Novavax, Inc. (NVAX) Company Bio
Novavax, Inc. focuses on discovering, developing, and commercializing recombinant nanoparticle vaccines and adjuvants. The company was founded in 1987 and is based in Gaithersburg, Maryland.
Latest NVAX News From Around the Web
Below are the latest news stories about NOVAVAX INC that investors may wish to consider to help them evaluate NVAX as an investment opportunity.
Smart Shorts: 7 Meme Stocks to Bet Against in 2024These seven meme stocks have surged as speculators declare "the coast is clear," but a big reversal for each of them may be forthcoming. |
3 Heavily Shorted Stocks That Still Won’t See a SqueezeThese are the heavily shorted stocks to avoid as they are likely to continue trending lower on the back of very weak fundamentals. |
Is Novavax Stock A Buy On Its Covid Vaccine Launch Spree?Novavax stock jumped this month as the company launched its updated Covid shot abroad. Is NVAX stock a buy or a sell right now? |
Owning 48% shares,institutional owners seem interested in Novavax, Inc. (NASDAQ:NVAX),Key Insights Significantly high institutional ownership implies Novavax's stock price is sensitive to their trading... |
3 Meme Stocks That Could Fade Away in 2024These are the meme stocks to avoid or sell as they have extremely weak fundamentals and are unlikely to recover from a financial perspective. |
NVAX Price Returns
1-mo | -20.60% |
3-mo | -0.42% |
6-mo | -33.98% |
1-year | -28.23% |
3-year | -97.25% |
5-year | -56.62% |
YTD | -0.42% |
2023 | -53.31% |
2022 | -92.81% |
2021 | 28.30% |
2020 | 2,701.76% |
2019 | -89.18% |
Continue Researching NVAX
Want to see what other sources are saying about Novavax Inc's financials and stock price? Try the links below:Novavax Inc (NVAX) Stock Price | Nasdaq
Novavax Inc (NVAX) Stock Quote, History and News - Yahoo Finance
Novavax Inc (NVAX) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...